



PRESSRELEASE

PledPharma will be presenting company's drug development programs at today's CMD in Stockholm

Stockholm, March 26, 2019. PledPharma AB (publ) hosts today the company's capital markets day (CMD) in Stockholm, where it will be presenting company's development programs, including opportunities for indication expansion of PledOx[®] and the results from Aladote[®]'s POP study.

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company hosts today a capital markets day for analysts, investors and media in Stockholm, Sweden.

Members from the management team and two key opinion leaders (KOL) will be presenting company's drug development programs PledOx[®] and Aladote[®]. Broader presentation regarding unmet medical need, the development programs, commercial potential including opportunities for indication expansion of PledOx[®] will be presented.

Speakers at the CMD include the Chairman of the Board, Håkan Åström, the CEO, Nicklas Westerholm and members from the management team as well as two key opinion leaders, Dr. James Dear, Edinburgh University and Prof. Per Pfeiffer, Odense University. Lars Hevren, head of research at Vator Securities and previously healthcare analyst will moderate the event.

Venue details:

Time: Tuesday March 26th, at 10:00-15:00 CET

Venue: Redeye, Mäster Samuelsgatan 42, 10th floor, Stockholm

Presentations will be held in English.

The CMD will be broadcasted live at www.redeye.se/live/pled-kapitalmarknadsdag-2019

For further information, please contact:

Nicklas Westerholm, CEO

Phone +46 (0)73 354 20 62

nicklas.westerholm@pledpharma.se

Yilmaz Mahshid, CFO

Phone +46 (0)72 231 68 00

yilmaz.mahshid@pledpharma.se



PledPharma

About PledPharma

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's most advanced project PledOx[®] is being developed to reduce nerve damage associated with chemotherapy. A global phase III program is ongoing. The drug candidate Aladote[®] is being developed to reduce the risk of acute liver injury associated with acetaminophen poisoning. A proof of principle study has been successfully completed and will serve as the basis for the continued development. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company's Certified Adviser (tel +46 8 463 83 00, certifiedadviser@penser.se). For more information, see <http://www.pledpharma.com/>